Q-omics provides the consensus-scored GAPDHP19 profile across patient tissues and cancer cell-line models. GAPDHP19 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, GAPDHP19 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, GAPDHP19 RNA expression shows 3,506 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight COAD, LUSC, and HNSC as cancer lineages where GAPDHP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP19 survival associations across molecular data types. GAPDHP19 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP19 RNA expression–survival associations across cancer types. High GAPDHP19 expression shows unfavorable associations in SKCM, ACC, SARC and PAAD, but favorable associations in COAD and READ. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .016). Together, the overview and detailed table identify COAD as the clearest survival context for GAPDHP19 RNA expression.
This table summarizes GAPDHP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP19 shows higher tumor expression in LUSC. The LUSC box plot shows higher GAPDHP19 RNA expression in tumor versus normal tissue (log2 FC = +0.009, t-test p = .024).
This table shows molecular features associated with GAPDHP19 in patient tissues and cancer cell lines. In patient samples, GAPDHP19 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
